Whether soluble thrombomodulin could have antitumour effects in patients has not been formally investigated; however, it has demonstrated clinical benefits in managing disseminated intravascular coagulation in cancer patients and has the potential for direct effects on tumour burden as well as in aberrant thrombosis 52. Here, THBD is linked to neoplasm.